Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8460916 | 0.90 | RAB9A (0.63) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL12321357 | 0.85 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL15452407 | 0.85 | HTT (0.71) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL10939397 | 0.85 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL29190961 | 0.84 | SMN1; SMN2 (0.69) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL29190948 | 0.84 | SMN1; SMN2 (0.65) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL29190958 | 0.84 | HTT (0.73) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL29190944 | 0.83 | RAB9A (0.52) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL29191035 | 0.83 | MAPK7 (0.57) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 | |
| SCHEMBL30874537 | 0.83 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2RAB9ANPC1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903339-B | Substituted N-phenyl-bipyrrolidine carboxamides and their therapeutic use | SANOFI AVENTIS | 2012-06-27 | — | — | CN | claimed |
| CN-117886734-A | Heterocyclic amide compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-04-16 | — | — | CN | disclosed |
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-116096714-A | Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections | 安力高医药股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4165037-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | Aligos Therapeutics, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| WO-2021252491-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-8618159-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| CN-101903339-B | Substituted N-phenyl-bipyrrolidine carboxamides and their therapeutic use | SANOFI AVENTIS | 2012-06-27 | — | — | CN | disclosed |
| EP-2212282-B1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2011-09-21 | — | — | EP | disclosed |
| CN-101903339-A | Substituted N-phenyl-bipyrrolidine carboxamides and their therapeutic use | SANOFI AVENTIS | 2010-12-01 | — | — | CN | disclosed |
| EP-2212282-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-08-04 | — | — | EP | disclosed |
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| WO-2009052065-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
| CN-1922149-A | Pyrrole and pyrazole daao inhibitors | SEPRACOR INC (US) | 2007-02-28 | — | — | CN | disclosed |
| US-4511575-A | Antidiabetic pyrrolecarboxylic acids | PFIZER INC. (US) | 1985-04-16 | — | — | US | disclosed |
| US-4511576-A | Antidiabetic pyrrolecarboxylic acids | PFIZER INC. (US) | 1985-04-16 | — | — | US | disclosed |
| US-4351843-A | LOWERING BLOOD GLUCOSE | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4282242-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173897-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | ALDH1A1 911/4885SMN1; SMN2 2093/4885RAB9A 3245/4885 |
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 2039/4885SMN1; SMN2 239/4885RAB9A 347/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 2039/4885SMN1; SMN2 239/4885RAB9A 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.